AS/Spondyloarthritis
The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review these and other news, journal reports and announcements from this past week.
Dr. John Cush RheumNow
2 years 10 months ago
Open label, noninferiority study TNFi withdrawal in 64 PsA & 58 axSpA pts. 2/3 tapered by dz activity T2T strategy (N=81) & 1/3 continued TNFi. At 12 mos. LDA seen in 69% w/ Tapering (~avg 53% dose) vs 73% no-tapering group (91% dose) https://t.co/K6WFaesyRt https://t.co/zqo6nVGtqW
Dr. John Cush RheumNow
2 years 10 months ago
534 PsA & 470 AS pts (SERENA study) on Secukinumab for avg of ~88wks - 5.8% PsA & 8.9% AS pts had sudden stop of SEC (for avg ~25wks) (reasons? Mostly AE 58% or pt decision 10%). While TJC & SJC increased, dz control returned w/ restarting SEC https://t.co/GFxj3b06Ra https://t.co/B2ubakq8Ql
Dr. John Cush RheumNow
2 years 10 months ago
The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/ZqMAc8jV3U https://t.co/3iCGnzsPI5
Charlie Clements ClementsCharl96
2 years 10 months ago
Nice table from the Poddubny et al., (2021) study which looks at some of the different characteristics between Axial SpA vs Axial PsA.
Axial PsA tends to have;
- Less frequent IBP
- Less HLAB27 +‘ve
- More frequent C-spine involvement https://t.co/XXQKBSfSQq
Dr. John Cush RheumNow
2 years 10 months ago
The ACR is developing a new clinical practice guideline for systemic autoimmune rheumatic disease with interstitial lung disease (ILD). The Call for Public Comment is open until September 29, 2022. https://t.co/UxXDbGEQlh https://t.co/zGoBpbKLTC
Dr. John Cush RheumNow
2 years 10 months ago
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/xchK5ETmg3 https://t.co/F9klsUE5er
Dr. John Cush RheumNow
2 years 10 months ago
How to predict IBD in AS/SpA? Study of 82 SpA pts undergoing colonoscopy showed: Rectal bleeding, diarrhea, abdominal pain, high Dz activity and calprotectin levels were suggestive of abnormal ileum inflammation and risk of IBD https://t.co/10PKp7uwmx https://t.co/tnU5tu6Ffp
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.
Dr. John Cush RheumNow
2 years 10 months ago
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/b9Qa6fL9eM https://t.co/6nRu0iuP1a
Dr. John Cush RheumNow
2 years 10 months ago
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/1aSrRsLkel https://t.co/gmh155ty6w
Laurent ARNAUD Lupusreference
2 years 10 months ago
✅ Probably one of my most important slides ⬇️
WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Dr. John Cush RheumNow
2 years 10 months ago
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
https://t.co/8bAoqp79Mg https://t.co/K2Z1LwPTiS
Dr. John Cush RheumNow
2 years 11 months ago
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
Researchers examined two PsA and AS cohorts - patients with PsA with axial disease and isolated axial patients with AS with psoriasis.
Poster Hall